Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.50 |
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9480324 | 0.86 | IDO1 (0.50) | IDO1PNMTPKMTAAR1LMNA | |
| SCHEMBL14002931 | 0.84 | IDO1 (0.48) | IDO1PNMTPKMTAAR1LMNA | |
| SCHEMBL16534760 | 0.82 | SLC6A2 (0.50) | IDO1PNMTPKMTAAR1LMNA | |
| SCHEMBL2423546 | 0.82 | SLC6A2 (0.50) | IDO1PNMTPKMTAAR1LMNA | |
| SCHEMBL29679143 | 0.82 | SLC6A2 (0.50) | IDO1PNMTPKMTAAR1LMNA | |
| SCHEMBL14520626 | 0.82 | SLC6A2 (0.50) | IDO1PNMTPKMTAAR1LMNA | |
| SCHEMBL3058311 | 0.82 | PNMT (0.52) | IDO1PNMTPKMTAAR1LMNA | |
| SCHEMBL28476371 | 0.82 | HSPA5 (0.39) | PKMTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL249276 | 0.80 | IDO1 (0.45) | IDO1PNMTPKMTAAR1LMNA | |
| SCHEMBL29786842 | 0.80 | IDO1 (0.45) | IDO1PNMTPKMTAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275077-A1 | Methods of Obtaining Optically Active Epoxides and Vicinal Diols from Styrene Oxides | OXYRANE (UK) LIMITED (GB) | 2009-11-05 | — | — | US | disclosed |
| US-20070281339-A1 | Methods For Obtaining Optically Active Epoxides and Vicinal Diols From Styrene Oxides | OXYRANE UK LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1756281-A2 | METHOD FOR THE PREPARATION OF OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM STYRENE EPOXIDES USING ENANTIOSELECTIVE EPOXIDE HYDROLASES DERIVED FROM YEASTS | CSIR (ZA) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005100569-A2 | METHODS FOR THE PREPARATION OF OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM STYRENE EPOXIDES USING ENANTIOSELECTIVE EPOXIDE HYDROLASES DERIVED FROM YEASTS | CSIR (ZA) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275077-A1 | Methods of Obtaining Optically Active Epoxides and Vicinal Diols from Styrene Oxides | EPHX2, EPHX1, DERA | IDO1 664/4885PNMT 416/4885PKM 4176/4885 |
| US-20070281339-A1 | Methods For Obtaining Optically Active Epoxides and Vicinal Diols From Styrene Oxides | DERA, ERG28, EPHX2 | IDO1 1534/4885PNMT 982/4885PKM 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.